Other potential predictive factors that have been reported in patients with hematologic malignancies include age, use of BCL2 inhibitors, use of JAK2 inhibitors, absolute lymphocyte count, and circulating CD4+, CD8+, and natural killer cell counts [7,8,9,23,32]. The gene discussed is BCL2; the disease is hematologic disorder.